Astellas completes strategic layout and upgrade in China

"The upgrade of the strategic structure of Astellas in China, which is an overall adjustment initiated positively based on the integrated planning of the company, will lay a solid foundation for the subsequent achievement of the group's strategic goals in the country," said Hiroshi Hamaguchi, president of the company's Greater China Commercial.

"As we all know, China's medical and health market is going through rapid development and changes, which compels enterprises to improve operational efficiency to maintain industrial competitiveness. Upon this update, the three entities could implement agile decision-making and lean management by virtue of their independence, to improve operation efficiency, further enhance each business segment's competitiveness with peers, and make concerted efforts under the highly unified strategic steering to inject new momentum into Astellas' development in China."

China has always been a vital market for Astellas' global growth. In the future, the company's strategies will still focus on breakthroughs in oncology, innovative drugs and therapy, he added.